Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$2.88 USD
+0.09 (3.23%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.89 +0.01 (0.35%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HBIO 2.88 +0.09(3.23%)
Will HBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HBIO
Bruker (BRKR) Q2 Earnings Meet Estimates
Mettler-Toledo (MTD) Surpasses Q2 Earnings and Revenue Estimates
HBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harvard Bioscience (HBIO) Q1 Earnings Match Estimates
Bruker (BRKR) Q1 Earnings Beat Estimates
Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?
Other News for HBIO
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript
HBIO Stock Earnings: Harvard Bioscience Misses Revenue for Q2 2024
Harvard Bioscience: Q2 Earnings Snapshot
Harvard Bioscience Announces Second Quarter 2024 Financial Results